These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 7882283)

  • 1. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma.
    Levesque MA; Katsaros D; Yu H; Zola P; Sismondi P; Giardina G; Diamandis EP
    Cancer; 1995 Mar; 75(6):1327-38. PubMed ID: 7882283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serological levels of mutated p53 protein are highly detected at early stages in breast cancer patients.
    Balogh GA; Mailo D; Nardi H; Corte MM; Vincent E; Barutta E; Lizarraga G; Lizarraga P; Montero H; Gentili R
    Exp Ther Med; 2010 Mar; 1(2):357-361. PubMed ID: 22993549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium.
    Minlikeeva AN; Freudenheim JL; Eng KH; Cannioto RA; Friel G; Szender JB; Segal B; Odunsi K; Mayor P; Diergaarde B; Zsiros E; Kelemen LE; Köbel M; Steed H; deFazio A; Jordan SJ; Fasching PA; Beckmann MW; Risch HA; Rossing MA; Doherty JA; Chang-Claude J; Goodman MT; Dörk T; Edwards R; Modugno F; Ness RB; Matsuo K; Mizuno M; Karlan BY; Goode EL; Kjær SK; Høgdall E; Schildkraut JM; Terry KL; Cramer DW; Bandera EV; Paddock LE; Kiemeney LA; Massuger LFAG; Sutphen R; Anton-Culver H; Ziogas A; Menon U; Gayther SA; Ramus SJ; Gentry-Maharaj A; Pearce CL; Wu AH; Kupryjanczyk J; Jensen A; Webb PM; Moysich KB; ;
    Cancer Epidemiol Biomarkers Prev; 2017 Sep; 26(9):1470-1473. PubMed ID: 28864456
    [No Abstract]   [Full Text] [Related]  

  • 4. Assessment of Adult Women With Ovarian Masses and Treatment of Epithelial Ovarian Cancer: ASCO Resource-Stratified Guideline.
    Vanderpuye VD; Clemenceau JRV; Temin S; Aziz Z; Burke WM; Cevallos NL; Chuang LT; Colgan TJ; Del Carmen MG; Fujiwara K; Kohn EC; Gonzáles Nogales JE; Konney TO; Mukhopadhyay A; Paudel BD; Tóth I; Wilailak S; Ghebre RG
    JCO Glob Oncol; 2021 Jun; 7():1032-1066. PubMed ID: 34185571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation Between Immunohistochemical Biomarkers Expression and Prognosis of Ovarian Carcinomas in Tunisian Patients.
    Ayadi L; Chaabouni S; Khabir A; Amouri H; Makni S; Guermazi M; Frikha M; Boudawara TS
    World J Oncol; 2010 Jun; 1(3):118-128. PubMed ID: 29147191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P53, bcl-2, ki-67 li (labeling index) status in benign, proliferative, and malignant ovarian surface epithelial neoplasms.
    Gursan N; Sipal S; Calik M; Gundogdu C
    Eurasian J Med; 2009 Apr; 41(1):10-4. PubMed ID: 25610057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor β signaling.
    Weissmueller S; Manchado E; Saborowski M; Morris JP; Wagenblast E; Davis CA; Moon SH; Pfister NT; Tschaharganeh DF; Kitzing T; Aust D; Markert EK; Wu J; Grimmond SM; Pilarsky C; Prives C; Biankin AV; Lowe SW
    Cell; 2014 Apr; 157(2):382-394. PubMed ID: 24725405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies.
    Le Page C; Huntsman DG; Provencher DM; Mes-Masson AM
    Cancers (Basel); 2010 May; 2(2):913-54. PubMed ID: 24281100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wild-type and mutant p53 mediate cisplatin resistance through interaction and inhibition of active caspase-9.
    Chee JL; Saidin S; Lane DP; Leong SM; Noll JE; Neilsen PM; Phua YT; Gabra H; Lim TM
    Cell Cycle; 2013 Jan; 12(2):278-88. PubMed ID: 23255126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic biomarkers in ovarian cancer.
    Huang J; Hu W; Sood AK
    Cancer Biomark; 2010-2011; 8(4-5):231-51. PubMed ID: 22045356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulation of the mitochondrial transport protein, Tim50, by mutant p53 contributes to cell growth and chemoresistance.
    Sankala H; Vaughan C; Wang J; Deb S; Graves PR
    Arch Biochem Biophys; 2011 Aug; 512(1):52-60. PubMed ID: 21621504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer.
    Ferrandina G; Fagotti A; Salerno MG; Natali PG; Mottolese M; Maneschi F; De Pasqua A; Benedetti-Panici P; Mancuso S; Scambia G
    Br J Cancer; 1999 Oct; 81(4):733-40. PubMed ID: 10574264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p21/WAF1 expression as related to p53, cell proliferation and prognosis in epithelial ovarian cancer.
    Anttila MA; Kosma VM; Hongxiu J; Puolakka J; Juhola M; Saarikoski S; Syrjänen K
    Br J Cancer; 1999 Apr; 79(11-12):1870-8. PubMed ID: 10206307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary endometrioid carcinoma of fallopian tube. Clinicomorphologic study.
    Rabczyński J; Ziółkowski P
    Pathol Oncol Res; 1999; 5(1):61-6. PubMed ID: 10079381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of the cell cycle inhibitor p27KIP1 is a new prognostic marker associated with survival in epithelial ovarian tumors.
    Newcomb EW; Sosnow M; Demopoulos RI; Zeleniuch-Jacquotte A; Sorich J; Speyer JL
    Am J Pathol; 1999 Jan; 154(1):119-25. PubMed ID: 9916926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status.
    Smith-Sørensen B; Kaern J; Holm R; Dørum A; Tropé C; Børresen-Dale AL
    Br J Cancer; 1998 Aug; 78(3):375-81. PubMed ID: 9703286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug resistance in ovarian cancer - the role of p53.
    Petty R; Evans A; Duncan I; Kurbacher C; Cree I
    Pathol Oncol Res; 1998; 4(2):97-102. PubMed ID: 9654593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53-Dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells.
    Zamble DB; Jacks T; Lippard SJ
    Proc Natl Acad Sci U S A; 1998 May; 95(11):6163-8. PubMed ID: 9600935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P53 expression in stage I squamous cell lung cancer.
    Moldvay J; Strausz J; Egerváry M; Agócs L; Bocsi J; Schaff Z
    Pathol Oncol Res; 1998; 4(1):8-13. PubMed ID: 9555114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extent of apoptosis in ovarian serous carcinoma: relation to mitotic and proliferative indices, p53 expression, and survival.
    McMenamin ME; O'Neill AJ; Gaffney EF
    Mol Pathol; 1997 Oct; 50(5):242-6. PubMed ID: 9497913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.